within Pharmacolibrary.Drugs.ATC.L;

model L01EG04_1
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.18,
    Cl             = 0.00015833333333333332,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.219,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01EG04_1</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Sirolimus, also known as rapamycin, is an immunosuppressant drug primarily used to prevent organ transplant rejection. It inhibits the mammalian target of rapamycin (mTOR), thereby suppressing T-cell proliferation and activation. Sirolimus is FDA-approved and is used in clinical practice, especially in renal transplantation.</p><h4>Pharmacokinetics</h4><p>Population PK in adult kidney transplant patients; results from model fitting to trough concentrations following multiple oral dosing.</p><h4>References</h4><ol><li><p>Kirchner, GI, et al., &amp; Manns, MP (2004). Clinical pharmacokinetics of everolimus. <i>Clinical pharmacokinetics</i> 43(2) 83–95. DOI:<a href=\"https://doi.org/10.2165/00003088-200443020-00002\">10.2165/00003088-200443020-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/14748618/\">https://pubmed.ncbi.nlm.nih.gov/14748618</a></p></li><li><p>Adams, DM, et al., &amp; Azizkhan, RG (2016). Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies. <i>Pediatrics</i> 137(2) e20153257–None. DOI:<a href=\"https://doi.org/10.1542/peds.2015-3257\">10.1542/peds.2015-3257</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26783326/\">https://pubmed.ncbi.nlm.nih.gov/26783326</a></p></li><li><p>Lee, KJ, et al., &amp; Chaturvedi, RR (2015). Pharmacokinetics of sirolimus-eluting stents implanted in the neonatal arterial duct. <i>Circulation. Cardiovascular interventions</i> 8(5) –. DOI:<a href=\"https://doi.org/10.1161/CIRCINTERVENTIONS.114.002233\">10.1161/CIRCINTERVENTIONS.114.002233</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25940522/\">https://pubmed.ncbi.nlm.nih.gov/25940522</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01EG04_1;
